CTKB: Cytek Biosciences, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-06 | 13G amendment | Integrated Core Strategies (US) LLC | 7.20% | SEC | |
| 2026-08-04 | New 13G stake | Boston Partners | 5.91% | SEC |
Institutional ownership (Q2 2026)
154 institutions reported holding $349.27M of Cytek Biosciences, Inc. on Form 13F (165 the quarter before). 27 opened a new position and 38 sold out. Shares held by institutions: -4%.
| Largest holders | Shares | Value |
|---|---|---|
| BlackRock, Inc. | 9,578,643 | $42.43M |
| MILLENNIUM MANAGEMENT LLC | 9,338,010 | $41.37M |
| Boston Partners | 7,660,943 | $33.94M |
| HHLR ADVISORS, LTD. | 6,657,030 | $29.49M |
| Topline Capital Management, LLC | 6,283,450 | $27.84M |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,939,597 | $21.88M |
| GEODE CAPITAL MANAGEMENT, LLC | 3,059,573 | $13.56M |
| DIMENSIONAL FUND ADVISORS LP | 2,616,257 | $11.59M |
| STATE STREET CORP | 2,566,121 | $11.37M |
| GOLDMAN SACHS GROUP INC | 2,167,515 | $9.60M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.